<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Chromosome band 11q23 is frequently involved in <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL) de novo, as well as in <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Five percent to 15% of patients treated with chemotherapy for a primary <z:hpo ids='HP_0002664'>neoplasm</z:hpo> develop therapy-related <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) that may show rearrangements, usually translocations involving band 11q23 or, less often, 21q22 </plain></SENT>
<SENT sid="2" pm="."><plain>These <z:hpo ids='HP_0001909'>leukemias</z:hpo> develop after a relatively short latent period and often follow the use of drugs that inhibit the activity of DNA-topoisomerase II (topo II) </plain></SENT>
<SENT sid="3" pm="."><plain>We previously identified a gene, MLL (myeloid-<z:hpo ids='HP_0005526'>lymphoid leukemia</z:hpo> or mixed-lineage <z:hpo ids='HP_0001909'>leukemia</z:hpo>), at 11q23 that is involved in the de novo <z:hpo ids='HP_0001909'>leukemias</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>We have studied 17 patients with t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, 12 of whom had cytogenetically detectable 11q23 rearrangements </plain></SENT>
<SENT sid="5" pm="."><plain>Ten of the 12 t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients had received topo II inhibitors and 9 of these, <z:hpo ids='HP_0000001'>all</z:hpo> with balanced translocations of 11q23, had MLL rearrangements on Southern blot analysis </plain></SENT>
<SENT sid="6" pm="."><plain>None of the patients who had not received topo II inhibitors showed an MLL rearrangement </plain></SENT>
<SENT sid="7" pm="."><plain>Of the 5 patients lacking 11q23 rearrangements, some of whom had monoblastic features, none had an MLL rearrangement, although 4 had received topo II inhibitors </plain></SENT>
<SENT sid="8" pm="."><plain>Our study indicates that the MLL gene rearrangements are similar both in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> that develops de novo and in t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>The association of exposure to topo II-reactive chemotherapy with 11q23 rearrangements involving the MLL gene in t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> suggests that topo II may play a role in the aberrant recombination events that occur in this region both in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> de novo and in t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
</text></document>